Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
暂无分享,去创建一个
Stefan Krauss | Peter Lindemann | Marc Nazaré | P. Lindemann | S. Krauss | S. Leonov | A. Majouga | Katina Lazarow | J. V. von Kries | M. Nazaré | L. Lehtiö | Y. Nkizinkiko | E. Obaji | U. R. Anumala | J. Waaler | A. Ignatev | P. A. Olsen | Sudarshan Murthy | Upendra Rao Anumala | Jo Waaler | Yves Nkizinkiko | Alexander Ignatev | Katina Lazarow | Petter Angell Olsen | Sudarshan Murthy | Ezeogo Obaji | Alexander G Majouga | Sergey Leonov | Jens Peter von Kries | Lari Lehtiö | K. Lazarow
[1] T. Pawson,et al. Structural Basis and Sequence Rules for Substrate Recognition by Tankyrase Explain the Basis for Cherubism Disease , 2011, Cell.
[2] H. Bregman,et al. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. , 2013, Journal of medicinal chemistry.
[3] Brandoch D. Cook,et al. Role for the Related Poly(ADP-Ribose) Polymerases Tankyrase 1 and 2 at Human Telomeres , 2002, Molecular and Cellular Biology.
[4] D. Chin,et al. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. , 2013, Journal of medicinal chemistry.
[5] S. Kaufmann,et al. PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.
[6] M. R. Purnell,et al. Novel inhibitors of poly(ADP-ribose) synthetase. , 1980, The Biochemical journal.
[7] Bernhard Lüscher,et al. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. , 2010, Trends in biochemical sciences.
[8] S. Krauss,et al. Tankyrases as drug targets , 2013, The FEBS journal.
[9] Marc W. Kirschner,et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.
[10] G. Drewes,et al. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. , 2013, Journal of medicinal chemistry.
[11] S. Krauss,et al. The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice , 2016, Diabetologia.
[12] M. D. Lloyd,et al. Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity. , 2017, Journal of medicinal chemistry.
[13] Oliver Distler,et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis , 2012, Nature Communications.
[14] Ryohei Katayama,et al. APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer , 2017, Molecular Cancer Therapeutics.
[15] Steve Schneider,et al. Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. , 2013, ACS medicinal chemistry letters.
[16] B. Shan,et al. Human Cytomegalovirus Infection Dysregulates the Canonical Wnt/β-catenin Signaling Pathway , 2012, PLoS pathogens.
[17] J. Behrens,et al. The canonical Wnt signalling pathway and its APC partner in colon cancer development , 2006, Gut.
[18] S. Krauss,et al. Tankyrases: Structure, Function and Therapeutic Implications in Cancer , 2014, Current pharmaceutical design.
[19] B. Durkacz,et al. (ADP-ribose)n participates in DNA excision repair , 1980, Nature.
[20] B. Durkacz,et al. The effect of inhibition of (ADP-ribose)n biosynthesis on DNA repair assayed by the nucleoid technique. , 1981, European journal of biochemistry.
[21] A. Ashworth,et al. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family , 2012, Nature Reviews Drug Discovery.
[22] H. Dinh,et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. , 2011, Cancer research.
[23] T. Pihlajaniemi,et al. para‐Substituted 2‐Phenyl‐3,4‐dihydroquinazolin‐4‐ones As Potent and Selective Tankyrase Inhibitors , 2013, ChemMedChem.
[24] H. Bregman,et al. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.
[25] S. Krauss,et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. , 2013, Cancer research.
[26] Steve Schneider,et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.
[27] S. Krauss,et al. Development and structural analysis of adenosine site binding tankyrase inhibitors. , 2016, Bioorganic & medicinal chemistry letters.
[28] D. Chin,et al. Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. , 2013, Journal of medicinal chemistry.
[29] Tobias Karlberg,et al. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. , 2017, Journal of medicinal chemistry.